Arbutus Biopharma Logo
Proof of RNAi in Man Strengthens Leadership Position of Tekmira's LNP Delivery Technology
10 janv. 2011 08h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Arbutus Biopharma Logo
Tekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial
22 déc. 2010 08h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference
24 nov. 2010 08h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 24, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Intellectual Property Portfolio Expands With Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation
22 nov. 2010 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today...